Basic information
- Standard SMILES
COC(=O)C(c1ccccc1)C1CCCCN1- InChIKey
DUGOZIWVEXMGBE-UHFFFAOYSA-N- Molecular formula
- C14H19NO2
- Average molar mass
- 233.31 g/mol
- Monoisotopic mass
- 233.14157885
Names & identifiers
- Preferred name
- Methylphenidate
- IUPAC
- methyl 2-phenyl-2-piperidin-2-ylacetate
- English name
- Ritalin
- Molecular formula
- C14H19NO2
- Molecular weight
- 233.31
Names & synonyms
Show more names
Database identifiers
- CAS
113-45-1- PubChem CID
- 4158
- DTXSID
DTXSID5023299- ChEMBL
CHEMBL796- ChEBI
CHEBI:84276- EC Number
- 204-028-6
- Nikkaji
- J5.133K
Properties
Computed structural properties
- XLogP
- 0.2
- Topological polar surface area
- 38.3 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 3
- Rotatable bonds
- 4
- Heavy atoms
- 17
- Formal charge
- 0
- Complexity
- 249
Physicochemical properties
- Melting point
- 74.5 °C · 74.5°C
- Boiling point
- 327 ℃ · 327℃
- Density
- 1.07 · 1.070
- refractive index
- 1.511 · 1.5110 (estimate)
- Flash point
- 152 ℃ · 152℃
- pka
- 9.51 · 9.51±0.10(Predicted)
- CAS DataBase Reference
- 113 · 113-45-1
- NCI Dictionary of Cancer Terms
- dexmethylphenidate
- FDA UNII
- 32 RH9MFGP · M32RH9MFGP
- ATC code
- 6 BA11 · N06BA11
- EPA Substance Registry System
- 2 · 2-Piperidineacetic acid, ?-phenyl-, methyl ester (113-45-1)
- Symbol(GHS)
- 8 · GHS08
- Signal word
- Warning
- Hazard statements
- 315 · H315-H302-H319-H341
- Precautionary statements
- 264 · P264-P280-P305+P351+P338-P337+P313P-P201-P202-P281-P308+P313-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501
- Hazardous Substances Data
- 113 · 113-45-1(Hazardous Substances Data)
- Toxicity
- 50 oral · LD50 oral in rat: 367mg/kg
Safety & regulation
Safety data
- Toxicity
- LD50 oral in rat: 367mg/kg
- Signal word
- Warning
- Symbol(GHS)
- GHS08
- Hazard statements
- H315-H302-H319-H341
- Precautionary statements
- P264-P280-P305+P351+P338-P337+P313P-P201-P202-P281-P308+P313-P405-P501-P264-P280-P302+P352-P321-P332+P313-P362-P264-P270-P301+P312-P330-P501
- Hazardous Substances Data
- 113-45-1(Hazardous Substances Data)
Chemistry & industry
Applications
HistoryMethylphenidate is a piperidine derivative that is a central nervous system stimulant. Methylphenidate, in its hydrochloride form, is the active ingredient in the common medication Ritalin. Methylphenidate was first synthesized from benzyl cyanide and 2-chloropyridine in Basel, Switzerland in 1944 by Ciba chemist Leandro Panizzon (1907 ).Panizzon named the substance Ritaline after his wife, whose nickname was Rita. Panizzon and Max Hartmann proposed an improved synthesis for methylphenidate and obtained a U.S. patent for its preparation in 1950 (U.S. Patent Number 2507631). In 1954, methylphenidate was patented for use as an agent for treating psychological disorders under the name Ritalin by the Ciba pharmaceutical company.(Ciba subsequently merged with the Geigy company to become Ciba-Geigy, and then Ciba-Geigy merged with Sandoz to form Novartis.) Methylphenidate was first used to reverse drug-induced coma. Ritalin was approved by the Food and Drug Administration (FDA) in 1955 and introduced in the United States in 1956 for several conditions including depression, senile behavior, lethargy, and narcolepsy. Hyperactive children were first treated with stimulants in 1937. Since methylphenidate first appeared on the market, its use for treating ADHD has steadily increased. It is the most commonly used medication for treating children diagnosed with ADHD.
UsesMethylphenidate's mode of action is not completely known, but it is believed that ADHD symptoms are related to the dopaminergic areas of the brain. Animal studies indicate that methylphenidate affects several neurotransmitters to counteract ADHD behavior. Methylphenidate binds to dopamine transporters in the presynaptic neuron, blocking the reuptake of dopamine and increasing extracellular dopamine. Methylphenidate also infl uences norepinephrine reuptake and infl uences serotonin to a minor degree. In addition to ADHD, methylphenidate is used for several other medical conditions.It continues to be used for narcolepsy. It has also been used in treating depression, especially in elderly populations. Methylphenidate has been suggested for use in the treatment of brain injury from stroke or brain trauma; it has also been suggested to improve appetite and the mood of cancer and HIV patients. Another use is for pain control and/or sedation for patients using opiates.Health concerns are associated with the use of methylphenidate.Some of the commonly reported adverse effects associated with its use are insomnia, nervousness, hypertension, headache, anorexia, and tachycardia;less common effects include weight loss, nausea, and angina. Studies have indicated that methylphenidate lead to liver tumors in mice, but limited studies on its carcinogenicity in animals have not led the FDA to change recommendations on its use. Because methylphenidate is a stimulant and readily available, it has a potential for drug abuse.
UsesStimulant.
Upstream & downstream products
Upstream raw materials
Downstream products
Additional notes
DefinitionChEBI: Methyl phenyl(piperidin-2-yl)acetate is a amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group. It is a member of piperidines, a methyl ester and a beta-amino acid ester.
Related reactions
Linked notes
Loading…